Single-cell profiling of the human primary motor cortex in ALS and FTLD

S. Sebastian Pineda^{1,2,3,4}, Hyeseung Lee^{3,4}, Brent E. Fitzwalter^{3,4}, Shahin Mohammadi^{2,3,10}, Luc J. Pregent⁵, Mahammad E. Gardashli⁵, Julio Mantero², Erica Engelberg-Cook⁵, Mariely DeJesus-Hernandez⁵, Marka van Blitterswijk⁵, Cyril Pottier^{6,7}, Rosa Rademakers^{5,6,7}, Bjorn Oskarsson⁸, Jaimin S. Shah⁸, Ronald C. Petersen⁸, Neill R. Graff-Radford⁸, Bradley F. Boeve⁸, David S. Knopman⁸, Keith A. Josephs⁸, Michael DeTure⁵, Melissa E. Murray⁵, Dennis W. Dickson⁵, Myriam Heiman^{3,4,9,*}, Veronique V. Belzil^{5,*}, Manolis Kellis^{1,2,3,*}

¹. Department of Electrical Engineering and Computer Science, MIT, Cambridge, MA, USA

². MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA

³. Broad Institute of MIT and Harvard, Cambridge, MA, USA

⁴. Picower Institute for Learning and Memory, Cambridge, MA, USA

⁵. Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA

⁶. VIB Center for Molecular Neurology, VIB, Antwerp, Belgium

⁷. Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium

⁸. Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA

⁹. Department of Brain and Cognitive Sciences, MIT, Cambridge, MA, USA

¹⁰. Current address: Insitro Inc. South San Francisco, CA, USA

* Co-corresponding authors.

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are two devastating and fatal neurodegenerative conditions. While distinct, they share many clinical, genetic, and pathological characteristics¹, and both show selective vulnerability of layer 5b extratelencephalic-projecting cortical populations, including Betz cells in ALS^{2,3} and von Economo neurons (VENs) in FTLD^{4,5}. Here, we report the first high resolution single-cell atlas of the human primary motor cortex (MCX) and its transcriptional alterations in ALS and FTLD across ~380,000 nuclei from 64 individuals, including 17 control samples and 47 sporadic and *C9orf72*-associated ALS and FTLD patient samples. We identify 46 transcriptionally distinct cellular subtypes including two Betz-cell subtypes, and we observe a previously unappreciated molecular similarity between Betz cells and VENs of the prefrontal cortex (PFC) and frontal insula. Many of the dysregulated genes and pathways are shared across excitatory neurons, including stress response, ribosome function, oxidative phosphorylation, synaptic vesicle cycle, endoplasmic reticulum protein processing, and autophagy. Betz cells and *SCN4B*+ long-range projecting L3/L5 cells are the most transcriptionally affected in both ALS and FTLD. Lastly, we find that the VEN/Betz cell-enriched transcription factor, POU3F1, has altered subcellular localization, co-localizes with TDP-43 aggregates, and may represent a cell type-specific vulnerability factor in the Betz cells of ALS and FTLD patient tissues.

Introduction

The primary motor cortex is essential for voluntary motor control, sending layer 5 intratelencephalic tract and pyramidal tract output projections to modulate the execution of movement^{6,7}. It is affected in multiple neurodegenerative conditions, including amyotrophic lateral sclerosis (ALS)^{2,3}, the most common motor neuron disorder^{8,9}, and the related frontotemporal lobar degeneration (FTLD)¹⁰, the second-most common early onset dementia^{8,9}.

While ALS and FTLD are distinct diagnoses, they show overlapping clinical, genetic, and pathological characteristics, suggesting they are part of the same disease spectrum¹. Clinically, 50% of patients diagnosed with either ALS or FTLD eventually develop symptoms of the other disease, and 20% of patients ultimately receive both diagnoses^{10–14}. Genetically, the most common causative mutation for both ALS and FTLD is a repeat expansion in the C9orf72-SMCR8 complex subunit (*C9orf72*)^{15,16,17}, with the same mutation leading to ALS or FTLD, even among mutation carriers of the same family. Pathologically, 95% of ALS and ~50% of FTLD patients show a common signature of cytoplasmic accumulation of transactive response DNA binding protein 43 (TDP-43)¹⁸, an RNA-binding protein critical for RNA processing^{18,19}.

We hypothesized that in addition to their shared clinical, genetic, and pathological characteristics, ALS and FTLD may also share a common mechanistic basis at the molecular and cellular level. Indeed, FTLD shows loss of large fork cells and von Economo neurons (VENs) in layer 5 of anterior cingulate, fronto-insular, and dorsolateral prefrontal cortices^{20–23}, and ALS shows loss of pyramidal tract upper motor neurons (UMNs), specifically Betz cells, in layer 5 of the primary motor cortex, which make direct corticospinal connections to spinal motor neurons^{2,24,25}. Moreover, VENs share molecular markers with Betz cells, including *CTIP2* and *FEZF2*²⁶, and recent studies suggest VENs may be extratelencephalic-projecting neurons²⁷ similar to Betz cells. Thus, we sought to characterize the vulnerability of neuronal cell types in both ALS and FTLD, with a particular focus on large extratelencephalic-projecting cortical layer 5 neurons using single-cell profiling.

We generated the first high-resolution single-cell molecular atlas of the human primary motor cortex and examined transcriptional alterations in ALS and FTLD across multiple neuronal, glial, and vascular cell types. We profiled ~380,000 nuclei from 64 individuals, including 17 control samples and 47 sporadic and *C9orf72*-associated ALS and FTLD patient samples. We defined 46 transcriptional subtypes including two subtypes of Betz cells that exhibit remarkably close molecular similarity to frontal insula and PFC VENs. We found that excitatory neurons in ALS and FTLD shared a significant number of differentially expressed genes across cell types and phenotypes. For both disorders and across genotypes, we observed the highest degree of transcriptional dysregulation in the Betz cells, and more surprisingly, the L3/L5 *SCN4B*+ long-range projecting neurons. Many of the dysregulated pathways were also common, including stress response, ribosome function, oxidative phosphorylation, synaptic vesicle cycle, endoplasmic reticulum protein processing, and autophagy. Through co-expression network analysis of Betz cells, we identified co-expressed gene modules and their hub genes, both confirming several with known prior associations with ALS and FTLD, and discovering novel ones. Analysis of one of the novel hub genes, the VEN/Betz-cell enriched gene *POU3F1*, revealed that the subcellular localization of the POU3F1 protein is altered and co-localizes with TDP-43 aggregates in Betz cells of ALS and FTLD brain tissue.

Results

Characterization of human primary motor cortex

We first sought to characterize the diversity of cell types and marker genes for both neuronal and non-neuronal cells in the human primary motor cortex. After applying stringent quality control metrics and cell filtering, we report 380,610 single-nucleus profiles across 64 primary motor cortex samples, corresponding to ~6000 post-quality control nuclei per donor (**Fig. 1a, Extended data table 1**, see Methods). Compared to previous studies²⁸, the number of human cells captured represents a 4-fold increase in cell count, 10-fold increase in the number of individuals, and substantial increase in cell level resolution (**Extended Data Figs. 1 and 2**).

We annotated 46 transcriptionally-distinct cell subpopulations (**Fig. 1b-f, Extended Data Figs. 1a and 3**), all of which were well-mixed and reproducible across individuals, sexes, genotypes, and phenotypes (**Extended Data Fig. 1b,d-f**) using our recently-developed single-cell data analysis toolkit, ACTIONet²⁹, and well-curated cell type-specific marker genes

We characterized 19 subtypes of excitatory neurons in six major groups (**Fig. 1b**). Translaminar pyramidal neurons spanning layers 2 through 5 formed the largest group, consisting of 6 subtypes based on layer-specific marker gene expression. These showed a gradient of layer-specific marker gene expression, with markers for adjacent layers enriched in adjacent regions of the cluster in a mostly linear fashion, consistent

with reports of non-discrete transcriptional identity of translaminar cortical excitatory neurons in mice³⁰. No subtype or cluster showed exclusive enrichment for layer 4 markers, consistent with previous reports that layer 4 is absent from agranular primary motor cortex, but adjacent subpopulations with layer 3 and layer 5 markers (Ex L3/L5) and layer 5 subtypes (Ex L5) showed overlapping expression of layer 4 markers. We also detected a distinct subtype of *SCN4B*⁺ cells expressing markers of both Layer 3 and Layer 5 at the layer 3/5 interface, which showed the highest expression of neurofilament genes *NEFL*, *NEFM*, and *NEFH*, indicative of large axon caliber neurons (**Extended Data Fig. 4c**). This population likely corresponds to *FEZF2*- L3/L5 long-range projecting neurons³¹, and are henceforth referred to as “L3/L5 LR” (**Fig. 1b**).

We identified four distinct subtypes of *FEZF2*/*CRYM*⁺ layer 5b neurons partitioned into two groups (**Fig. 1b**; denoted as “UMN PT” and “UMN CT”). The smaller of these two groups corresponded to two transcriptionally distinct subtypes (*BCL11B*/*EYA4* and *BCL11B*/*THSD4*) of giant pyramidal tract upper motor neurons (UMN PT), also known as Betz cells, which expressed higher levels of neurofilament gene *NEFH*, and highly-specific enrichment of the Betz and VEN identity marker *POU3F1*³² (**Extended Data Fig. 4c**). These cells possessed the highest average RNA content among all cell types (**Extended Data Fig. 2a**), indicating a large cell volume characteristic of giant Betz cells. Expression of key markers and expected Betz morphology was confirmed by immunofluorescence (IF) (**Fig. 2a**). These cells are of particular interest as they are known to be selectively vulnerable in ALS^{2,33–35}.

The larger group of the layer 5b *FEZF2*/*CRYM*⁺ cells (*PCP4*/*GRIK1* and *PCP4*/*SLC24A3*) was also largely enriched for several canonical UMN markers but was reduced in or lacked expression of the long-range projection markers *NEFH* and *SCN4B* (**Fig. 2b**, **Extended Data Fig. 4c**). Observation of these cells by IF (not shown) showed that they were also layer 5b pyramidal neurons, but appeared to be much smaller than Betz cells, leading us to conclude that these are likely the corticobulbar tract upper motor neurons (UMN CT) that innervate the cranial nerve nuclei, the reticular formation, and the red nucleus.

We identified a group of four transcriptionally similar excitatory neuron subtypes that showed selective enrichment for markers of layer 6b, and human orthologs of mouse layer 6 subplate-derived deep cortical neurons³⁶, as well as a cluster of layer 2/3 neurons with highly-specific expression of *NR4A2* (**Fig. 1b**).

We captured 16 distinct populations of cortical inhibitory neurons (**Fig. 1c**), spanning multiple, highly-resolved subtypes of somatostatin-expressing GABAergic interneurons (*NPY*⁺ and *NPY*⁻), parvalbumin-expressing basket and chandelier cells, 5HT3aR-expressing interneurons (*VIP*⁺ and *VIP*⁻), and two populations of the recently characterized rosehip interneurons³⁷ (*CA3*⁺ and *PMEPA1*⁺).

We also recovered all expected classes of cortical glial, vascular, and immune cell types, including oligodendrocytes, oligodendrocyte progenitors, two subtypes (protoplasmic, interlaminar) of astrocytes (**Fig. 1d**), fibroblasts, arterial and venous subtypes of endothelial cells, smooth muscle and pericyte mural cells, and T cells (**Fig. 1e**).

Overall, this dataset represents the largest and most comprehensive transcriptomic characterization of the human primary motor cortex to date. Given the well-curated and reproducible nature of these annotations across individuals, we were able to identify novel markers for all the identified subtypes (**Supplementary Data Table 1**), which will help guide future imaging and other experimental studies to dissect the diverse functional properties and roles of these cell types.

Motor cortex Betz cells are transcriptional analogues to frontal and temporal cortex VENs

We next asked whether our discovered clusters of Betz cells in the primary motor cortex share intrinsic molecular markers with VENs, motivated by the fact that: (1) Betz cells and VENs display enhanced vulnerability in ALS and FTLT respectively; (2) Betz cells are large extratelencephalic-projecting layer 5 neurons and VENs have been recently hypothesized to also be extratelencephalic-projecting layer 5 neurons²⁷.

To compare VENs and Betz cells at similar resolution, we used data from our recent single-cell profiling of the dorsolateral PFC³⁸ carried out in the context of schizophrenia, but focusing only on the subset of 24 pathologically normal individuals. Detailed clustering and annotation of 107,358 PFC excitatory neurons (**Extended Data Fig. 4a**) revealed a neurofilament-enriched layer 5b subtype with selective expression of *POU3F1* and co-expression of numerous Betz cell markers (**Extended Data Fig. 4c**), which we determined to be the VEN population.

Pairwise transcriptome-wide analysis revealed that almost all annotated excitatory populations in the MCX could be mapped to a synonymous subtype in the dorsolateral PFC, and that both MCX Betz cell subtypes mapped most specifically to the PFC VEN subtype ($r = 0.57$ and 0.61) (**Extended Data Fig. 4b**).

We then identified and compared the top 50 marker genes of UMN, L3/L5 LR, and VEN subtypes and found that Betz cells and VENs possessed nearly identical expression patterns across these genes, and that a subset of these markers were also highly expressed in L3/L5 LR neurons, but very few were shared with corticobulbar motor neurons (**Fig. 2b**).

When we compared our data with the VEN markers described in a recent, targeted single-cell study of frontal insula VENs²⁷, we again found that all reported markers, in addition to the previously described *CTIP2/BCL11B* and *FEZF2*²⁶, are also very specifically expressed in Betz cells and, to a lower extent, other layer 5 UMNs and L3/L5 LR cells. This analysis also confirmed the annotation of our PFC VEN cluster (**Fig. 2c**).

This finding reveals a close molecular similarity between the two cortical populations that display the most vulnerability in ALS and FTLN, and provides further evidence for the hypothesis that VENs are in fact extratelencephalic-projecting neurons.

Cell type-specific differential gene expression analysis of ALS and FTLN

We next performed cell type-specific pseudo-bulk differential expression analysis across all five phenotypes: sporadic ALS (sALS; $n=17$), *C9orf72*-associated ALS (c9ALS; $n=6$), sporadic FTLN (sFTLN; $n=13$), *C9orf72*-associated FTLN (c9FTLN; $n=11$), and pathologically normal (PN; $n=17$) (**Extended Data Table 1**). To ensure that we had sufficient power across all experimental groups for less abundant populations, we aggregated highly similar subtypes within the same group for differential expression analysis (e.g. we treated both transcriptional subtypes of Betz cells as a single population denoted as Ex UMN PT), and excluded In *SST/NPY+* and T cells which were insufficiently abundant across donors and disease groups, and too dissimilar to aggregate with other subtypes (**Extended Data Fig. 5**).

Although large layer 5 projection neurons would be expected to be the most affected in both ALS and FTLN, we expected to see alterations in other cortical layers as well due to spreading of cortical atrophy in late-stage disease. Indeed, we observed a large disparity in the number of dysregulated genes between excitatory neurons and all other cell populations across all phenotypes and found that all excitatory neurons across cortical layers displayed severe transcriptional dysregulation (**Fig. 3a,b**, **Supplementary Data Tables 2-5**).

Our analysis showed that a significant fraction of upregulated differentially expressed genes (DEGs) was shared across excitatory neurons and appeared across diseases and genotypes (**Extended Data Fig. 6**); most of these genes were differentially expressed only in excitatory neurons.

For example, we observed a pan-phenotypic (that is, present in both ALS and FTLN, either sporadic or *C9orf72*-associated) upregulation of a large number of nuclear-encoded mitochondrial respiratory complex I, III, IV, and V subunit-encoding genes, as well as the mitochondrial membrane transporter ADP/ATP translocase 1 (*SLC25A4*) and the mitochondrial stability regulator mitoregulin (*MTLN*), but not mitochondrial-encoded RNAs, which would be indicative of poor nuclei quality. We also observed a primarily upwards, dysregulation of a substantial fraction of ribosomal subunit-encoding genes belonging to both the cytoplasmic (RPL/S) and mitochondrial (MRPL/S) families, the former of which was dramatically higher in excitatory neurons of c9ALS patients compared to the other cohorts.

Of particular note was the pan-phenotypic upregulation of several other genes previously linked to ALS and FTLN, including several heat shock proteins (*HSP90AA1*, *HSP90AB1*, *HSPA8*), Calmodulin-1 (*CALM1*), and the DEAD-box transcription and splicing regulator *DDX24*, which were among the most highly upregulated genes and present in nearly every excitatory subtype and phenotype and a few inhibitory subtypes (**Extended Data Fig. 6**). As the heat shock response is activated to prevent proteins from denaturing and aggregating under stress conditions, the HSF1 pathway and various heat shock proteins have been studied in the context of ALS and FTLN³⁹⁻⁴¹. Indeed Arimoclomol, a co-inducer of the heat shock protein response that may enhance the HSF1 pathway⁴²⁻⁴⁴, is the focus of multiple clinical trials after delaying disease progression in mice⁴⁴, including a Phase II/III clinical trial for patients with rapidly progressive ALS caused by *SOD1* mutations⁴⁵. Recent results suggest this drug may have therapeutic benefits for FTLN as well⁴⁶. In addition, *CALM1* has been proposed as a potential biomarker of longevity in a *SOD1* mouse model⁴⁷, and *DDX24* was shown to be differentially expressed in ALS blood⁴⁸.

Neurofilament subunits (including *NEFL*, *NEFM*, *NEFH*, *INA*) were another notable class of genes driving the

common pan-phenotypic signature. Alterations to *NEFH*, which encodes neurofilament heavy (NHF), are uncommon but found in ALS^{49–51}, and overexpression of NFH leads to motor neuron degeneration in transgenic mice⁵². Neuronal cytoskeleton-associated proteins (including *STMN2*, *TUBB2A*, *HOOK2*) were also commonly upregulated genes in excitatory neurons. *STMN2* is highly expressed in the central nervous system⁵³, and its expression is increased after neuronal injury^{54,55}. Similar to *NEFH*, increased *STMN2* expression is also observed in other neurodegenerative diseases^{56–58} and has been linked to TDP-43 pathobiology. TDP-43 regulates the splicing of *STMN2*, and TDP-43 cytoplasmic re-localization leads to a truncated *STMN2* mRNA, reduced *STMN2* protein levels, and reduced neuronal outgrowth^{54,59–61}. Even though these changes in cytoskeletal genes were pan-neuronal, their magnitude of upregulation was particularly high in Betz cells for each phenotype (**Fig. 3d**, **Supplementary Data Tables 2-5**), suggesting a possible compensatory response against the degradation of axonal integrity, as Betz cells are most affected. In addition, the L3/L5 LR cell type showed a surprisingly similar, and sometimes more severe, degree of dysregulation of these genes, particularly the neurofilament-encoding genes, indicating that the broad dysregulation of long-range projecting cells is not limited to Betz cells. Lastly, a subtype of L5 cells (Ex L5 *LRRK1 COL21A1*) also showed extensive dysregulation that was particularly prominent in ALS (**Fig. 3b**), but their biological significance is not clear given our current understanding of this population.

Inhibitory neurons showed more heterogeneous disease signatures within and across phenotypes, and significantly less dysregulation overall (**Fig. 3a-b**). Nevertheless, interneuronal subtypes also showed upregulation of heat shock proteins and a few of the top-ranking excitatory DEGs, implying that these genes are part of a pan-neuronal disease or stress response (**Extended Data Fig. 6**). In contrast, all glial and vascular cell types showed little to no overlap in DEGs with either neuronal class or with each other and were overall among the least severely affected cell populations, irrespective of disease.

Across all recovered cell types, downregulated genes showed much more disease-specific patterns, with only a handful of genes appearing across cohorts. However, several genes with links to ALS and FTLN pathobiology were ubiquitously downregulated in neurons within each disease. In both genotypes of ALS, the glutamate receptor subunit-encoding gene *GRIN1*, and the ALS-linked poly(A) binding protein nuclear 1 (*PABPN1*)⁶² were two of the most downregulated genes in most neuronal subtypes. *PABPN1* contains a GCG repeat encoding a polyalanine tract expanded in oculopharyngeal muscular dystrophy (OPMD)⁶³, plays a role in the regulation of poly(A) site selection for polyadenylation⁶⁴, interacts with *TDP-43*, *MATR3* and *hnRNPA1*^{62,65,66}, three genes mutated in both ALS and FTLN^{67–69}, and is a suppressor of TDP-43 toxicity in ALS models⁶². The *C9orf72* gene itself was identified as differentially expressed in a small, non-specific subset of excitatory subtypes, and only in *C9orf72*-associated cohorts, but was only marginally downregulated in these patients.

Since the absolute number of DEGs in a cell population can be biased by various factors (e.g., number of cells, differences in endogenous gene expression across cell types, cellular RNA content), we computed the difference of the mean, transcriptome-wide distance across all cells between diseased and pathologically normal populations for all cell types and disease groups and used this distance as a disease severity score. This analysis revealed that across cell types, both FTLN cohorts showed a much stronger disease signature than ALS cohorts (**Fig. 3b**). It also showed that in all disease subgroups, L3/L5 LR and Betz cells exhibited the most drastic transcriptome-wide shift from the pathologically normal profile, with the former showing more dysregulation than the Betz population in three of the four groups (**Fig. 3b**). This suggests that while ALS- and FTLN-induced transcriptome perturbations may not be unique to Betz cells, these and the ill-defined L3/L5 LR cells, exhibit enhanced vulnerability in both ALS and FTLN relative to other cell types.

The same observation was not made for corticobulbar motor neurons, which showed a degree of transcriptional misregulation comparable to most other non-Betz excitatory neurons. Taken together, our results suggest that, in the primary motor cortex at a molecular level, *SCN4B/SV2C*+ L3/L5 long-range projecting cells (which are *FEZF2*- and were previously hypothesized to be intratelencephalic projecting³¹) and L5 Betz long-range extratelencephalic-projecting cells are the most affected cell types assessed in this study, for both ALS and FTLN. These cells, and to a lesser extent all other excitatory neurons, display dysregulation of several genes recognized to be genetically or mechanistically linked to ALS and FTLN.

Comparison of Betz cell DEGs across sporadic and *C9orf72*-associated samples showed strong agreement within genotypes of both ALS ($R = 0.84$) and FTLN ($R = 0.77$), with FTLN showing more heterogeneity (**Extended Data Fig. 7a**). All detected genotype-specific DEGs were uniquely perturbed in either sporadic or *C9orf72*-associated samples, with none of the highly altered genes showing anti-directional dysregulation in

either disease (**Fig 3d, Extended Data Fig. 7a**). Cross-phenotype comparisons showed weaker, but still respectable correlations, with most uniquely dysregulated or anti-directional perturbations being specific for ALS or FTLT (**Extended Data Fig. 7b**). The marginal differences in transcriptional perturbations observed between genotypes is consistent with the fact that, in the absence of genotype information, sporadic and *C9orf72*-associated cases of ALS and FTLT are clinically indistinguishable. More broadly, a high-level comparison of DEGs across all cell types revealed that, similar to Betz cells, all other cell types showed modest intra-subtype agreement in transcriptional alterations, even across dissimilar disease groups where few or no other subtype pairs exhibited any degree of similarity (**Extended Data Fig. 8**).

Betz cell biological pathway alterations in ALS and FTLT

As Betz cells exhibited a large transcriptome-wide shift in both ALS and FTLT and are known to be affected in both diseases¹⁰, we sought to identify trait-specific putative gene regulatory networks that are specifically altered in this cell population. For this purpose, we used weighted gene co-expression network analysis (WGCNA), which summarizes co-expressed gene clusters into “modules” and is widely utilized to identify highly correlated genes via unsupervised clustering^{70–72}. Using pseudo-bulk transcriptional data converted from the single-nuclear transcriptional data described above, our analysis revealed 46 modules specific to ALS and FTLT Betz cells (**Fig. 4a**). Among these, 19 modules significantly correlated with clinical traits (sporadic and *C9orf72*-associated ALS and FTLT; **Fig. 4b**). We found that sporadic FTLT had the most correlated modules, followed by c9FTLT, c9ALS, and sALS. Notably, the “darkorange2” module correlated with both sporadic ALS and FTLT groups. Interestingly, all four members of the stathmin family of genes (*STMN1*, *STMN2*, *STMN3*, and *STMN4*) were identified as top hub genes for this module, having expression values highly correlated with the “darkorange2” module’s eigengene values⁷³ (**Supplementary Data Table 6**). Many hub genes of the “darkorange2” module were also known ALS- and FTLT-associated genes, including *DCTN1*, *CHCHD10*, *SOD1*, *SQSTM1*, *VAPB*, *VCP*, *UBQLN2*, *PFN1*, and *PRNP*, a known *C9orf72* age-of-onset modifier^{74–76}.

Analysis of hub genes for the 19 modules revealed many shared pathways from both “blue” and “darkorange2” modules (**Fig. 4c, Supplementary Data Table 7**). The significant “blue” and “darkorange2” pathways were related to stress response, and included terms such as ribosome, oxidative phosphorylation, synaptic vesicle cycle, protein processing in endoplasmic reticulum, and autophagy. Importantly, impaired stress response is indeed a widely recognized pathological mechanism for both ALS and FTLT, and includes oxidative stress, endoplasmic reticulum stress, disruption of major protein clearance pathways such as ubiquitin-proteasome system and autophagy, altered stress granules dynamics, unfolded protein response, and DNA damage/repair response^{77–79}. Also of interest, nuclear pore complex (NPC) and nucleocytoplasmic transport (NCT) defects were common terms for sporadic and *C9orf72*-associated ALS and FTLT, and hub genes included nuclear pore complex *NUP50*, nuclear transport receptor *TNPO3*, and arginine methyltransferase *PRMT1*. NPC and aberrant NCT have received a great deal of interest in recent years after being first observed in *C9orf72*-associated diseases and then sporadic cases^{80,81}. The hub genes identified here are also known modifiers of NPC and NCT, and are associated with multiple neurodegenerative diseases including ALS and FTLT⁸², including *Nup50* mutations demonstrated to be genetic suppressors of TDP-43 toxicity^{83,84}. Disruption in NPC and NCT affects the localization of multiple proteins involved in the stress response such as ribosomal proteins and stress granule-associated RNA binding proteins⁸⁴. A number of hub genes identified encode proteins interacting with G3BP1 (*CAPRIN1*, *CSDE1*, *POLR2B*, *EIF3G*, *DDX3X*, *NUFIP2*, *EEF2*), which is known to specifically bind to the Ras-GTPase-activating protein, a key regulator of NCT^{85,86}. Of interest, dysregulated NPCs were shown to be degraded via upregulation of the ESCRT-III/Vps4 Complex in *Drosophila* models of *C9orf72* ALS⁸⁷, and components of the four core subunits of the ESCRT-III complex (*CHMP4B*, *CHMP1A*, *CHMP5*) and of other ESCRT complexes (*VPS28* and *VPS25*)⁸⁸ were also “darkorange2” hub genes.

Further inspection of hub genes revealed other interesting regulatory networks that are potentially contributing to ALS and FTLT pathogenesis, such as *SRSF3* and *SRSF8*. SRSF proteins are pre-mRNA splicing factors with multiple functions, including mRNA export from the nucleus⁸⁹. Some SRSF proteins have been found to be sequestered by *C9orf72*-associated RNA foci (*SRSF1*; *SRSF2*), and *SRSF1*, *SRSF3*, *SRSF7* were shown to have increased binding to the GGGGCC (G₄C₂) *C9orf72* expanded repeat⁹⁰, potentially overriding normal nuclear retention, encouraging nuclear export of repeat-expanded pre-mRNAs, and consequently leading to repeat-associated non-AUG (RAN) translation and dipeptide repeats (DPR) in *C9orf72*-associated diseases^{91,92}. Other hub genes included the RNA-G4s helicase *DDX3X*, encoding a protein involved in transcriptional regulation, pre-mRNA splicing, and mRNA export, and part of the DEAD-box protein family characterized by a conserved Asp-Glu-Ala-Asp (DEAD) motif⁹³. *DDX3X* associates with 5'-UTR RNA G-quadruplexes (rG4s)-containing transcripts⁹⁴, which is especially relevant for *C9orf72*-associated ALS and

FTLD, as the G₄C₂ C9orf72 expanded repeat leads to a repeat-length-dependent accumulation of rG4-containing transcripts⁹⁵. Notably, DDX3X was shown to directly bind G₄C₂ RNAs, consequently suppressing RAN translation, DPR production, and aberrant nucleocytoplasmic transport; its helicase activity is essential for such translation repression⁹⁶. *EIF2AK2*, another hub gene, encodes the protein kinase R (PKR) which plays a key role in mRNA translation, transcriptional control, and regulation of apoptosis⁹⁷, and is regulated by double-stranded RNAs or double-stranded RNA-binding proteins⁹⁸. *TIA1*, a gene mutated in both ALS and FTLD⁹⁹ and a stress granule marker that colocalizes with TDP-43 inclusions in ALS and FTLD¹⁰⁰, has been demonstrated to be essential for appropriate activation of the PKR-mediated stress response¹⁰¹. A direct connection between *EIF2AK2* and TDP-43 was demonstrated when induced TDP-43 toxicity in flies upregulated phosphorylation of *EIF2AK2*¹⁰². In addition, *MARK2*, a hub gene in the “lightcyan” module, encodes a protein involved in the stability control of microtubules. *MARK2* specifically phosphorylates eIF2 α in response to proteotoxic stress and is activated via phosphorylation in ALS¹⁰³. Inhibition of eIF2 α -phosphorylation has been demonstrated to mitigate TDP-43 toxicity¹⁰².

We also observed hub genes involved in N6-methyladenosine (m6A) RNA metabolism such as *RBM15B*, a component of a regulatory protein complex that regulates m6A “writer”, and *ALKBH5*, an m6A “eraser” involved in global m6A demethylation. Genes involved in the degradation of m6A-containing mRNAs such as deadenylase *CNOT7* and *RPP25*, a shared component of ribonuclease (RNase) P and RNase mitochondrial RNA-processing (MRP), were also found as hub genes in the “darkorange2” module. These observations indicate potential disruption of the m6A RNA methylome in Betz cells.

Additional WGCNA analysis of the cell type showing the highest transcriptional dysregulation, the L3/L5 LR cells, identified 20 modules significantly correlated with the different clinical traits (**Extended Data Fig. 9**). Pathway analysis of hub genes from these modules revealed many overlapping pathways altered in the Betz cells, suggesting disruptions of similar pathways in both cell types.

Together, our findings highlight various ‘hub’ genes and biological pathways with prior association with ALS and FTLD, reinforcing the notion that transcriptional dysregulation can be used not only as a molecular marker of disease, but also as a resource to identify new candidate driver genes. Considering putative driver genes, of particular interest is the VEN/Betz cell enriched alanine-repeat encoding gene *POU3F1*¹⁰⁴, which appeared as a top 10% “darkorange2” module hub gene (kME value of 0.87, 97th among 1,287 total hub genes). The observation that *POU3F1* is highly enriched in VENs and Betz cells (**Fig. 2, Extended Data Fig. 4c**), that it contains a GCG repetitive sequence similar to *PABPN1*, and that its dysregulation leads to axonal loss¹⁰⁵, suggest possible involvement in ALS and FTLD pathobiology.

POU3F1 Alterations in ALS

As short (8-13 repeats) alanine-encoding GCG expansions in the *PABPN1* gene cause OPMD⁶³, which is characterized by TDP-43-positive aggregates¹⁰⁶, it is possible that the 11-alanine repeat encoding hub gene *POU3F1* represents an intrinsic vulnerability factor of Betz cells and VENs in ALS and FTLD by similarly influencing TDP-43 aggregation. To investigate whether *POU3F1* co-localizes with TDP-43 aggregates in ALS and FTLD, we conducted indirect immunofluorescent staining of ALS and FTLD primary motor cortex post-mortem tissue samples (**Fig. 5**). We found that *POU3F1* displayed a broad subcellular distribution in Betz cells in pathologically normal tissue. However, in ALS and FTLD patient tissue, we observed a shift in *POU3F1* subcellular localization, which now exhibited a punctate morphology in the cytosol of Betz cells. Strikingly, we found that this altered localization of *POU3F1* often co-localized with TDP-43 aggregate puncta in Betz cells (**Fig. 5**), suggesting that TDP-43 may co-aggregate with this Betz cell-enriched transcription factor and contribute to cell type-specific dysfunction in ALS and FTLD. Taken together, these results suggest that the Betz/VEN-enriched transcription factor *POU3F1* is mislocalized, consequently impairing its normal cellular functions in ALS and FTLD patient Betz cells.

Discussion

Our study represents the largest and most comprehensive molecular atlas of the human primary motor cortex, revealing previously unknown characteristics of this brain region, as well as the first documentation of single-cell-level molecular alterations in ALS and FTLD. These will serve as a resource to not only the ALS and FTLD research communities, but also to the human genomics field at large.

We report the existence of at least two distinct classes of Betz cells, as well as a previously unappreciated close molecular similarity between Betz cells of the motor cortex and VENs of the frontal insula and dorsolateral PFC, uncovering a novel link between these vulnerable brain regions and lending further evidence to the notion of an ALS-FTLD pathological spectrum. Further studies will be needed to understand how the two

classes of Betz cells differ at a functional level, as well as in the context of ALS and FTLD.

We reveal that, in addition to these Betz cells, a recently identified *SCN4B*/*SV2C*⁺ long-range projecting L3/L5 cell type is the most transcriptionally affected in both ALS and FTLD. In the original description³¹, it was postulated that this cell type's markers represent a shift of expression from preferentially layer 5 in mouse to preferentially layer 3 in human³¹. The authors went on to suggest that this population reflects a unique set of human layer 3 pyramidal neurons that may have human (or primate)-specific long-range intracortical projections³¹. Our studies confirmed that these cells are *FEZF2*⁻, but that they otherwise express several layer 5 markers (we thus assign them L3/L5 identity), as well as all three neurofilament triplet genes, supporting the idea that they are indeed long-range projection neurons. Further studies will be needed to better understand the cellular and molecular characteristics of this cell population in the normal human brain, as well as in the context of ALS and FTLD, in which they appear to be even more vulnerable than Betz cells. Despite no widespread reports of cell death in this population, some previous pathological studies have suggested that alterations in ALS motor cortex may in fact begin in some pyramidal cells of layer 3¹⁰⁷. Interestingly, our motor cortex profiles show that these L3/L5 *SCN4B*/*SV2C*⁺ cells are second to Betz cells in terms of sharing molecular similarity to VENs (**Fig. 2b,c**), further reinforcing that these intrinsic molecular characteristics, when possessed by cortical neurons, confer vulnerability to cell loss or dysregulation in ALS and FTLD.

Our studies also reveal many ALS and FTLD-associated pathways and likely driver genes, including the VEN/Betz-cell enriched gene *POU3F1*, for which we demonstrated that its encoded protein co-aggregates with TDP-43 in Betz cells of ALS and FTLD brain tissue. *POU3F1* has been ascribed various roles in the developing nervous system, including in neuronal fate commitment¹⁰⁸, motor neuron identity^{32,109}, oligodendrocyte differentiation¹¹⁰, and Schwann cell differentiation¹¹¹. Developmental perturbations to *POU3F1* activity result in axonal abnormalities, myelination abnormalities, and premature death, with knockout of *POU3F1* resulting in a fatal breathing defect^{105,112,113}. However, *POU3F1* expression patterns change during development, and its role in the adult nervous system is poorly understood, as is its role in ALS and FTLD pathobiology. Future studies will be needed to understand the role of *POU3F1* and other markers shared exclusively across Betz, VEN, and L3/L5 LR cells that our results suggest may be key factors underlying the differential vulnerability of these cell types in ALS and FTLD pathogenesis.

Figure 1. Single-nucleus RNA-seq profiling of primary motor cortex in ALS and FTLD. **a.** Experimental design. **b-e.** Detailed ACTIONet sub-plots of annotated transcriptional subtypes of excitatory neurons (**b**), inhibitory neurons (**c**), glial cells (**d**), and vascular cells (**e**). Insets in upper left corners highlight (in red) clusters of the full ACTIONet plot (**Fig. 1a** right, and **Extended data figure 1a**) shown in each sub-plot. Sub-plot cluster colors correspond to those in the full plot. Clusters of motor and L3/L5 long-range projecting neuron subtypes highlighted in (**b**). **f.** Pairwise Pearson correlation of scaled, mean transcriptome-wide gene counts across annotated subtypes.

Figure 2. Characterization of ALS and FTLD implicated cell populations. **a.** Representative images showing indirect immunofluorescent labeling of Betz cell markers Mu-Crystallin (*CRYM*) and POU3F1 in pathologically normal tissue. Scale bar = 20µm. **b.** Differential expression of top 50 marker genes of annotated subtypes corresponding to previously described and newly identified differentially vulnerable cell types in ALS and FTLD. Right-most column shows expression of markers in VENs of the dorsolateral PFC. Top 25 markers of each subtype labeled on the left. **c.** Violin plots showing single-cell-level expression of VEN marker genes from Hodge *et al.* (2020) in annotated excitatory subtypes of MCX and VENs of PFC. Both Betz cell clusters in MCX (MCX Ex L5b *BCL11B*) and the VEN cluster in PFC (PFC EX L5b *POU3F1*) exhibit high expression of nearly every identified VEN marker. Dots denote population mean. MCX: motor cortex; PFC: prefrontal cortex.

Figure 3. Differential gene expression analysis. **a.** Absolute number of DEGs detected per cell type per disease group (absolute log2-fold change Z-score > 1, FDR-adjusted $p < 0.005$). **b.** Disease score (transcriptomic distance from pathologically normal) of each cell type per disease group. Left: Absolute distance. Right: Column-wise Z-score of distances. **c.** Overlap of detected pyramidal tract upper motor neuron (Betz cell) group DEGs across disease groups. **d.** Top up and down regulated pan-phenotypic and phenotype-specific DEGs (FDR-adjusted $p < 0.005$). ns: Not statistically significant; NA: absent in data set.

Figure 4. WGCNA analysis of Ex UMN PT (Betz) cluster in ALS and FTLD. a. Dendrogram showing result of unsupervised hierarchical clustering of modules identified by WGCNA. b. Pearson correlation of module eigengenes with disease groups. Modules significantly correlated with ALS and/or FTLD are shown, with the number of hub genes displayed on the right of each module's name. c. Significant KEGG pathways enriched in hub genes of "blue", "brown", "steelblue", and "darkorange2" modules. Numbers in each circle represent the number of hub genes in each pathway from the corresponding module.

Figure 5. POU3F1 is enriched in CRYM+ cells and displays altered subcellular localization in ALS and FTLD patient tissues. Representative images showing indirect immunofluorescent labeling of POU3F1 and TDP-43 (*TARDBP*) in Betz cells of pathologically normal (PN), sporadic ALS (sALS), *C9orf72*-associated ALS (c9ALS), sporadic FTLD (sFTLD), and *C9orf72*-associated FTLD (c9FTLD) patient tissues. Arrows indicate select regions displaying colocalized, punctate morphology of POU3F1 and TDP-43 fluorescent signals. Scale bar = 10µm.

Extended Data Figure 1. ACTIONet clustering results colored by attribute. a-f. Full ACTIONet plots (380,610 cells) colored by transcriptional subtype (a), donor individual (b), major cell class (c), disease phenotype (d), disease genotype (e), and donor sex (f).

Extended Data Figure 2. Gene expression complexity across annotated transcriptional subtypes. a. Distribution of total unique molecular identifier (UMI) counts per transcriptional subtype. **b.** Distribution of total unique genes detected per transcriptional subtype.

Extended Data Figure 3. Taxonomy of annotated subtypes. Dendrogram: Hierarchical clustering of transcriptional similarity by mean cluster expression of all genes expressed in > 0.5% of cells (19,953 genes). Identical to dendrogram on left side of **Figure 1f**. Heatmap: Visualization of the expression pattern of the top 200 marker genes per transcriptional subtype (2,683 genes). Color denotes row-wise Z-score of normalized expression.

Extended Data Figure 4. Cross-region comparison of identified excitatory neuron subtypes. a. ACTIONNet plot of excitatory neurons (107,358 cells) from Ruzicka *et al.* (2020). Cluster identified as von Economo neurons (VENs) highlighted. **b.** Cross-region, pairwise Pearson correlation of normalized, transcriptome-wide gene expression across excitatory subtypes. Names of clusters corresponding to Betz and VEN subtypes highlighted in red. **c.** Relative expression heatmaps of neurofilament subunits and select Betz, VEN, L3/L5 LR, and layer 5b marker genes. Legend (top) denotes clusters (highlighted in red) corresponding to Betz cells (left) and VENs (right).

Extended Data Figure 5. Mapping of annotations of transcriptional subtypes to differential expression analysis group. a. Highly similar cell populations of less abundant subtypes were aggregated to ensure sufficient cell counts and donor representation across all disease groups. Arrows show how adjacent subtype clusters were aggregated. Groups marked as “excluded” had insufficient cell counts or donor representation for downstream analyses.

Extended Data Figure 6. Top upregulated and downregulated DEGs in neuronal populations. Heatmaps of top 100 most upregulated and downregulated genes across cell types and disease groups for excitatory (a) and inhibitory (b) neuron populations (absolute log2-fold change Z-score > 1 and FDR-adjusted $p < 0.005$). Top 50 most upregulated and top 20 most downregulated across subtypes by mean row expression shown right of each heatmap. Many of the most upregulated DEGs observed in excitatory neurons were shared across subtypes and disease groups. Inhibitory neurons showed a more cell and phenotype specific response, but a subset of the common excitatory DEGs were also present and shared across inhibitory subtypes.

Extended Data Figure 7. Comparison of Betz cell DEGs across genotypes and phenotypes. a. Scatter plots of cross-genotype comparison of statistically significant Betz cell DEGs within ALS (left) and FTLT (right) cohorts. Top 10 most up and down regulated genes labeled. **b.** Scatter plots of cross-phenotype comparison of statistically significant Betz cell DEGs between ALS and FTLT. Top 10 most up, down, and anti-directionally regulated genes labeled. FDR-adjusted $p < 0.005$ for all comparisons.

Extended Data Figure 9. WGCNA analysis of Ex L3/L5 *SCN4B/SC2C* (L3/L5 LR) cluster in ALS and FTLD. **a.** Dendrogram showing result of unsupervised hierarchical clustering of modules identified by WGCNA. **b.** Pearson correlation of module eigengenes with disease groups. Modules significantly correlated with ALS and/or FTLD are shown, with the number of hub genes displayed on the right of each module's name. **c.** Significant KEGG pathways enriched in hub genes of “brown”, “lightsteelblue1”, “floralwhite”, “sienna3”, “lightcyan”, “lightcyan1”, “palevioletred3”, and “lightgreen” modules. Numbers in each circle represent the number of hub genes in each pathway from the corresponding module.

Group	Cohort size <i>n</i>	Sex female % <i>n</i>	Post-mortem interval median (IQR), <i>h</i>	Age at onset of cognitive symptoms median (IQR), <i>y</i>	Age at onset of motor symptoms median (IQR), <i>y</i>	Age at death median (IQR), <i>y</i>	Survival after onset median (IQR), <i>y</i>
sALS	17	0.53	10.00 (7.00-15.00)	n/a	62.59 (55.98-69.80)	64.28 (60.29-71.62)	2.94 (1.42-3.67)
c9ALS	6	0.50	16.00 (15.25-16.00)	n/a	60.98 (57.57-62.04)	62.61 (59.70-65.50)	1.88 (1.62-2.46)
sFTLD	13	0.46	5.50 (4.50-10.50)	61.15 (58.45-64.15)	n/a	71.23 (70.55-74.64)	10.72 (9.02-12.42)
c9FTLD	11	0.36	6.00 (5.00-6.50)	64.15 (60.80-75.25)	n/a	75.00 (71.94-78.50)	6.44 (4.00-13.00)
PN	17	0.53	6.00 (5.13-15.75)	n/a	n/a	80.25 (64.98-89.59)	n/a

Extended Data Table 1. Summarized characteristics of profiled brain samples. Calculations include all individuals with available information: sex (64/64), post-mortem interval (PMI; 52/64), age at onset cognitive (22/24), age at onset motor (23/23), survival after onset (45/47). *n*: sample size; IQR: interquartile range; *h*: hours; *y*: years.

Supplementary Data Table 1. Novel marker genes for annotated subtypes. Table of top 100 subtype-specific marker genes identified by ACTIONet.

Supplementary Data Table 2. Differential gene expression results - sALS. Raw results of limma pseudo-bulk differential expression analysis for sporadic ALS cohort.

Supplementary Data Table 3. Differential gene expression results – c9ALS. Raw results of limma pseudo-bulk differential expression analysis for *C9orf72*-associated ALS cohort.

Supplementary Data Table 4. Differential gene expression results - sFTLD. Raw results of limma pseudo-bulk differential expression analysis for sporadic FTLD cohort.

Supplementary Data Table 5. Differential gene expression results – c9FTLD. Raw results of limma pseudo-bulk differential expression analysis for *C9orf72*-associated FTLD cohort.

Supplementary Data Table 6. UMN PT hub genes identified by WGCNA. Tables of hub genes corresponding to significant co-expression modules of UMN PT group.

Supplementary Data Table 7. KEGG pathway enrichment for UMN PT hub genes. Tables of pathway enrichment results for UMN PT group hub genes identified by WGCNA. Genes were compared against the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database.

Methods

Human sample selection and preparation.

Human tissue analysis was conducted as exempt human research, considering frozen post-mortem brain samples obtained from the Neuropathology Laboratory at the Mayo Clinic (Jacksonville, FL USA) were not specifically collected for this study. All cases were carefully analyzed by experienced and certified neuropathologists. TDP-43 pathology was confirmed in all ALS and FTLN samples based upon current consensus criteria, which investigates cortical and subcortical distribution of TDP-43 neuropathologic inclusions^{114,115}. A section of the cerebellum was screened for *C9orf72*-related pathology with P62 immunohistochemistry¹¹⁶. For all *C9orf72*-associated cases, repeat expansions were confirmed via Southern blot. Extent of upper and lower motor neuron involvement was investigated in all samples using Luxol fast blue and IBA-1 immunohistochemistry in the motor cortex, midbrain, and medulla. Motor neuron degeneration was confirmed in all ALS cases and found absent from all FTLN and control samples selected.

We selected a total of 64 age- and sex-matched individuals with sporadic ALS (sALS; $n=17$), *C9orf72*-associated ALS (c9ALS; $n=6$), sporadic FTLN (sFTLN; $n=13$), *C9orf72*-associated FTLN (c9FTLN; $n=11$), or found pathologically normal ($n=17$). Each cohort included similar numbers of male and female samples (sALS 8:9; c9ALS 3:3; sFTLN 7:6; c9FTLN 7:4; PN 8:9). Each *C9orf72*-associated disease cohort included patients with a positive family history of either ALS or FTLN. All other disease cases selected were considered sporadic, which is representative of the majority of patients: no family history and no defined genetic risk factor (no mutation in *SOD1*, *TARDBP*, *FUS*, *C9orf72*, *NEK1*, *GRN*, *MAPT*, or *TBK1*). For each brain selected, approximately 300mg of the primary motor cortex was dissected by the Mayo Clinic Neuropathology Laboratory.

Isolation of nuclei from post-mortem frozen human brain tissue for single nuclear RNA-sequencing.

Nuclei isolation protocol was adapted from Lee et al.¹¹⁷ All procedures were performed on ice. Tissue was homogenized in 700 μ L of homogenization buffer (320 mM sucrose, 5 mM CaCl_2 , 3 mM $\text{Mg}(\text{CH}_3\text{COO})_2$, 10 mM Tris HCl [pH 7.8], 0.1 mM EDTA [pH 8.0], 0.1% NP-40, 1 mM β -mercaptoethanol, and 0.4 U/ μ L SUPERase In RNase Inhibitor (ThermoFisher Scientific, Waltham MA) with a 2 mL KIMBLE Dounce tissue grinder (MilliporeSigma, Burlington MA) using 10 strokes with loose pestle followed by 10 strokes with tight pestle. From the mouse tissue samples the entire striatum was homogenized. From the human tissue samples 100 mg of grey matter was sectioned and homogenized. Homogenized tissue was filtered through a 40 μ m cell strainer and mixed with 450 μ L of working solution (50% OptiPrep density gradient medium (MilliporeSigma, Burlington MA), 5 mM CaCl_2 , 3 mM $\text{Mg}(\text{CH}_3\text{COO})_2$, 10 mM Tris HCl [pH 7.8], 0.1 mM EDTA [pH 8.0], and 1 mM β -mercaptoethanol). The mixture was then slowly pipetted onto the top of an OptiPrep density gradient containing 750 μ L of 30% OptiPrep Solution (134 mM sucrose, 5 mM CaCl_2 , 3 mM $\text{Mg}(\text{CH}_3\text{COO})_2$, 10 mM Tris HCl [pH 7.8], 0.1 mM EDTA [pH 8.0], 1 mM β -mercaptoethanol, 0.04% NP-40, and 0.17 U/ μ L SUPERase In RNase Inhibitor) on top of 300 μ L of 40% OptiPrep Solution (96 mM sucrose, 5 mM CaCl_2 , 3 mM $\text{Mg}(\text{CH}_3\text{COO})_2$, 10 mM Tris HCl [pH 7.8], 0.1 mM EDTA [pH 8.0], 1 mM β -mercaptoethanol, 0.03% NP-40, and 0.12 U/ μ L SUPERase In RNase Inhibitor) inside a Sorenson Dolphin microcentrifuge tube (MilliporeSigma, Burlington MA). Nuclei were pelleted at the interface of the OptiPrep density gradient by centrifugation at 10,000 $\times g$ for 5 min at 4°C using a fixed angle rotor (FA-45-24-11-Kit). The nuclear pellet was collected by aspirating ~100 μ L from the interface and transferring to a 2.5 mL Eppendorf tube. The pellet was washed with 2% BSA (in 1x PBS) containing 0.12 U/ μ L SUPERase In RNase Inhibitor. The nuclei were pelleted by centrifugation at 300 $\times g$ for 3 min at 4°C using a swing-bucket rotor (S-24-11-AT). Nuclei were washed three times with 2% BSA and centrifuged under the same conditions. The nuclear pellet was resuspended in 100 μ L of 2% BSA.

Sequencing data preprocessing and analysis

Droplet-based snRNA sequencing libraries were prepared using the Chromium Single Cell 3' Reagent Kit v3 (10x Genomics, Pleasanton CA) according to the manufacturer's protocol and sequenced on a NovaSeq 6000 at the Broad Institute Genomics Platform. FASTQ files were aligned to the pre-mRNA annotated human reference genome GRCh38. Cell Ranger v4.0 (10x Genomics, Pleasanton CA) was used for genome alignment and feature-barcode matrix generation.

We used the ACTIONet^{29,118} and scran¹¹⁹ R packages to normalize, batch correct, and cluster single-cell gene counts. A curated set of known cell type-specific markers was used to annotate individual cells with their expected cell type and assign a confidence score to each annotation. We removed cells with high mitochondrial RNA content, abnormally low or high RNA content (relative to the distribution of its specific

cluster), ambiguous overlapping profiles resembling dissimilar cell types (generally corresponding to doublet nuclei), and cells corresponding to graph nodes with a low k -core or low centrality in the network (generally corresponding to high ambient RNA content or doublet nuclei).

Cell type-specific pseudo-bulk differential gene expression (DGE) analysis was performed using ACTIONet and limma¹²⁰ for sufficiently abundant cell types using age, sex, and disease group as design covariates and gene-wise single-cell-level variance as weights for the linear model. We found Braak stage to be a poor predictor of gene expression and omitted it from the design formula. Genes were considered differentially expressed if they had an FDR-corrected p-value < 0.005 and an absolute log2-fold change > 1 standard deviation for that cell type relative to the pathologically normal control group. To ensure that DGE results were reproducible and robust to differences in cell type abundance, we sampled with replacement equal numbers of individuals and cells per individual for each cell type and repeated the pseudo-bulk analysis. Lastly, we repeated the analyses using DESeq2¹²¹ as the model-fitting algorithm in lieu of limma to ensure replicability across methods. In all cases DGE results were consistent and we used the pseudo-bulk limma results for all downstream analyses. Pathway analysis was performed using the g:Profiler¹²² R package.

WGCNA

We used R package WGCNA^{70–72} to perform the weighted correlation network analysis on pseudo-bulk expression profiles. A signed network was constructed with the UMN PT and L3/L5 LR clusters shown in the ACTIONet plot of excitatory neurons (**Fig. 1b**). The co-expression similarity was raised to the power $\beta = 8$ to arrive at the network adjacency (R^2 is 0.8 when $\beta = 8$). The modules were identified using the R function *blockwiseConsensusModules* with minModuleSize = 30. Hub genes (genes with highest module membership) in each consensus module were identified using the R function *signedKME*⁷³. Pathway analysis was performed using the R package gprofiler2¹²² considering only protein-coding hub genes with kME value > 0.6.

Immunofluorescent labeling and confocal microscopy

Patient tissues were embedded in Allan Scientific™ Neg-50™ Frozen Section Medium (Thermo Scientific #6502), cryosectioned to 20µm thick, and transferred to glass slides (VWR #48311-703). Next, the tissues were subject to 100% ice-cold acetone (Sigma-Aldrich #320110) for 10 minutes followed by 15 minutes of tris-buffered saline with 0.25% Triton X-100 then blocked for 1 hour in tris-buffered saline with Tween 20 solution at 0.05% (BioRad #161-0781) supplemented with sterile 2% Normal Donkey serum (Abcam #ab138579) and 0.1% fish gelatin (Sigma-Aldrich #G7765). Next, the slides were incubated overnight at 4 degrees Celsius in a slide humidity chamber with primary antibodies POU3F1 (Millipore Sigma MABN738) and TDP-43 (ProteinTech 10782-2-AP) or CRYM (Abcam ab220085). Next, the slides were washed and incubated with Donkey anti-Mouse IgG (H+L) 488nm and Donkey anti-Rabbit IgG (H+L) 546nm (ThermoFisher #A-21202, A-10040, respectively) for Figure 5a. The slides were washed and incubated with Donkey anti-Mouse IgG (H+L) 488nm and Donkey anti-Rabbit IgG (H+L) 647nm (ThermoFisher #A-21202, #A-31573, respectively) for Figure 5b. Following additional washes, a 10 mg/mL stock of Hoechst 33342, Trihydrochloride, Trihydrate (ThermoFisher #H1399) was used at 1µL per 10mL of washing solution for 10 minutes. Next, the tissues were treated with a solution containing TrueBlack (Biotium) at 50µL per 1 mL of 70% ethanol for 10 seconds, then washed with tris-buffered saline solution (no detergent). Tissues were then mounted using ProLong™ Gold Antifade Mountant (ThermoFisher #P36930). Mounted slides were imaged on a Zeiss Observer.Z1 LSM 700 confocal microscope (Carl Zeiss AG, Oberkochen, Germany) using a EC Plan-Neofluar 40X/1.30 Oil DIC M27 objective. Z-stack images were max-projected using Fiji¹²³.

Acknowledgements

The work was supported by grants from the National Institutes of Health (NIH), Mitsubishi Tanabe Pharma Holdings America, Inc., the JPB Foundation, the Robert Packard Center for ALS Research at Johns Hopkins, the LiveLikeLou Foundation, the Gerstner Family Foundation, the Mayo Clinic Center for Individualized Medicine, and the Cure Alzheimer's Fund. NIH NS100802 to M.H.; NIH AG067151 to V.V.B.; NIH AG054012, AG058002, AG062377, NS110453, NS115064, AG067151, AG062335, MH109978, MH119509, HG008155 to M.K.; NIH 5T32EB019940-05 to S.S.P.; NIH NS110994 to M.V.B.; NIH AG37491 to K.A.J.. H.L. was supported by a postdoctoral fellowship from the JPB Foundation, and B.E.F. was supported by a postdoctoral fellowship from the Hereditary Disease Foundation. Brain samples were provided by the Neuropathology Laboratory at the Mayo Clinic (Jacksonville, FL USA). We would like to thank all study participants for donating their brain to research, and Sami Barmada, M.D., Ph.D., for his professional input.

Data Availability

Raw and processed sequencing data, including annotated count matrices, associated with Figure 1 will be available on NCBI GEO upon publication.

Code Availability

Code used in this study is available upon reasonable request.

Author Contributions

S.S.P., H.L., and J.M. carried out single-cell profiling. S.S.P., H.L., and S.M. carried out computational analyses. B.E.F. carried out experimental validations. L.J.P., M.E.G., E.E.-C., M.D.-H., M.V.B., C.P., R.R., B.O., J.S.S., R.C.P., N.R.G.-R., B.F.B., D.S.K., K.A.J., M.D., M.E.M., D.W.D., and V.V.B. provided biological samples and phenotype/genotype information. M.H., M.K., and V.V.B. co-directed the work. S.S.P., H.L., B.E.F., M.H., V.V.B., and M.K. wrote the manuscript with input from all authors.

Competing Interest Declaration

The authors have no competing interests.

Supplementary Information

Supplementary information will be made available at <http://compbio.mit.edu/scALS/>.

Corresponding Author

Correspondence should be addressed to: mheiman@mit.edu, manoli@mit.edu, belzil.veronique@mayo.edu

References

1. Couratier, P., Corcia, P., Lautrette, G., Nicol, M. & Marin, B. ALS and frontotemporal dementia belong to a common disease spectrum. *Rev. Neurol.* **173**, 273–279 (2017).
2. Hammer, R. P., Jr, Tomiyasu, U. & Scheibel, A. B. Degeneration of the human Betz cell due to amyotrophic lateral sclerosis. *Exp. Neurol.* **63**, 336–346 (1979).
3. Brettschneider, J. *et al.* Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. *Ann. Neurol.* **74**, 20–38 (2013).
4. Kim, E.-J. *et al.* Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia. *Cereb. Cortex* **22**, 251–259 (2012).
5. Nana, A. L. *et al.* Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. *Acta Neuropathol.* **137**, 27–46 (2019).
6. McColgan, P., Joubert, J., Tabrizi, S. J. & Rees, G. The human motor cortex microcircuit: insights for neurodegenerative disease. *Nat. Rev. Neurosci.* **21**, 401–415 (2020).
7. Ebbesen, C. L. & Brecht, M. Motor cortex — to act or not to act? *Nature Reviews Neuroscience* vol. 18 694–705 (2017).
8. Marin, B. *et al.* Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. *Int. J. Epidemiol.* **46**, 57–74 (2017).
9. Cronin, S., Hardiman, O. & Traynor, B. J. Ethnic variation in the incidence of ALS: a systematic review. *Neurology* **68**, 1002–1007 (2007).
10. Burrell, J. R., Kiernan, M. C., Vucic, S. & Hodges, J. R. Motor neuron dysfunction in frontotemporal dementia. *Brain* **134**, 2582–2594 (2011).
11. Giordana, M. T. *et al.* Dementia and cognitive impairment in amyotrophic lateral sclerosis: a review. *Neurol. Sci.* **32**, 9–16 (2011).
12. Gordon, P. H. *et al.* The range and clinical impact of cognitive impairment in French patients with ALS: a cross-sectional study of neuropsychological test performance. *Amyotroph. Lateral Scler.* **12**, 372–378 (2011).
13. Lomen-Hoerth, C., Anderson, T. & Miller, B. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. *Neurology* **59**, 1077–1079 (2002).

14. Ringholz, G. M. *et al.* Prevalence and patterns of cognitive impairment in sporadic ALS. *Neurology* **65**, 586–590 (2005).
15. DeJesus-Hernandez, M. *et al.* Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* **72**, 245–256 (2011).
16. Renton, A. E. *et al.* A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. *Neuron* **2011/09/29**, (2011).
17. Abramzon, Y. A., Fratta, P., Traynor, B. J. & Chia, R. The Overlapping Genetics of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. *Front. Neurosci.* **14**, 42 (2020).
18. Neumann, M. *et al.* Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science* **314**, 130–133 (2006).
19. Ling, S.-C., Polymenidou, M. & Cleveland, D. W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. *Neuron* **79**, 416–438 (2013).
20. Kim, E.-J. *et al.* Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia. *Cereb. Cortex* **22**, 251–259 (2012).
21. Santillo, A. F. & Englund, E. Greater loss of von Economo neurons than loss of layer II and III neurons in behavioral variant frontotemporal dementia. *Am. J. Neurodegener. Dis.* **3**, 64–71 (2014).
22. Santillo, A. F., Nilsson, C. & Englund, E. von Economo neurones are selectively targeted in frontotemporal dementia. *Neuropathol. Appl. Neurobiol.* **39**, 572–579 (2013).
23. Fajardo, C. *et al.* Von Economo neurons are present in the dorsolateral (dysgranular) prefrontal cortex of humans. *Neurosci. Lett.* **435**, 215–218 (2008).
24. Hughes, J. T. Pathology of amyotrophic lateral sclerosis. *Adv. Neurol.* **36**, 61–74 (1982).
25. Nihei, K., McKee, A. C. & Kowall, N. W. Patterns of neuronal degeneration in the motor cortex of amyotrophic lateral sclerosis patients. *Acta Neuropathol.* **86**, 55–64 (1993).
26. Cobos, I. & Seeley, W. W. Human von Economo neurons express transcription factors associated with Layer V subcerebral projection neurons. *Cereb. Cortex* **25**, 213–220 (2015).
27. Hodge, R. D. *et al.* Transcriptomic evidence that von Economo neurons are regionally specialized extratelencephalic-projecting excitatory neurons. *Nat. Commun.* **11**, 1172 (2020).
28. Yao, Z. *et al.* An integrated transcriptomic and epigenomic atlas of mouse primary motor cortex cell types.

bioRxiv 2020.02.29.970558 (2020) doi:10.1101/2020.02.29.970558.

29. Mohammadi, S., Davila-Velderrain, J. & Kellis, M. A multiresolution framework to characterize single-cell state landscapes. *Nat. Commun.* **11**, 5399 (2020).
30. Tasic, B. *et al.* Adult mouse cortical cell taxonomy revealed by single cell transcriptomics. *Nat. Neurosci.* **19**, 335–346 (2016).
31. Zeng, H. *et al.* Large-scale cellular-resolution gene profiling in human neocortex reveals species-specific molecular signatures. *Cell* **149**, 483–496 (2012).
32. Machado, C. B. *et al.* Reconstruction of phrenic neuron identity in embryonic stem cell-derived motor neurons. *Development* **141**, 784–794 (2014).
33. Geevasinga, N., Menon, P., Özdinler, P. H., Kiernan, M. C. & Vucic, S. Pathophysiological and diagnostic implications of cortical dysfunction in ALS. *Nat. Rev. Neurol.* **12**, 651–661 (2016).
34. Huynh, W. *et al.* Assessment of the upper motor neuron in amyotrophic lateral sclerosis. *Clin. Neurophysiol.* **127**, 2643–2660 (2016).
35. Maekawa, S. *et al.* Cortical selective vulnerability in motor neuron disease: a morphometric study. *Brain* **127**, 1237–1251 (2004).
36. Molyneaux, B. J., Arlotta, P., Menezes, J. R. L. & Macklis, J. D. Neuronal subtype specification in the cerebral cortex. *Nat. Rev. Neurosci.* **8**, 427–437 (2007).
37. Boldog, E. *et al.* Transcriptomic and morphophysiological evidence for a specialized human cortical GABAergic cell type. *Nat. Neurosci.* **21**, 1185–1195 (2018).
38. Ruzicka, W. B. *et al.* Single-cell dissection of schizophrenia reveals neurodevelopmental-synaptic axis and transcriptional resilience. *medRxiv* (2020).
39. Kalmar, B., Lu, C.-H. & Greensmith, L. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol. *Pharmacol. Ther.* **141**, 40–54 (2014).
40. Gomez-Pastor, R., Burchfiel, E. T. & Thiele, D. J. Regulation of heat shock transcription factors and their roles in physiology and disease. *Nat. Rev. Mol. Cell Biol.* **19**, 4–19 (2018).
41. Mordes, D. A. *et al.* Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients. *Acta Neuropathol Commun* **6**, 55 (2018).
42. Hargitai, J. *et al.* Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat

- shock factor-1. *Biochem. Biophys. Res. Commun.* **307**, 689–695 (2003).
43. Kalmar, B. *et al.* Upregulation of heat shock proteins rescues motoneurons from axotomy-induced cell death in neonatal rats. *Exp. Neurol.* **176**, 87–97 (2002).
44. Kieran, D. *et al.* Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. *Nat. Med.* **10**, 402–405 (2004).
45. Benatar, M. *et al.* Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. *Neurology* **90**, e565–e574 (2018).
46. Ahmed, M. *et al.* 1 Amplifying the heat shock response ameliorates pathology in mouse and human models of 2 ALS and FTD. <https://www.researchsquare.com/article/rs-152813/latest.pdf>.
47. Calvo, A. C. *et al.* Genetic biomarkers for ALS disease in transgenic SOD1(G93A) mice. *PLoS One* **7**, e32632 (2012).
48. van Rheenen, W. *et al.* Whole blood transcriptome analysis in amyotrophic lateral sclerosis: A biomarker study. *PLoS One* **13**, e0198874 (2018).
49. Figlewicz, D. A. *et al.* Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. *Hum. Mol. Genet.* **3**, 1757–1761 (1994).
50. Al-Chalabi, A. *et al.* Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. *Hum. Mol. Genet.* **8**, 157–164 (1999).
51. Tomkins, J. *et al.* Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS). *Neuroreport* **9**, 3967–3970 (1998).
52. Collard, J. F., Côté, F. & Julien, J. P. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. *Nature* **375**, 61–64 (1995).
53. Chauvin, S. & Sobel, A. Neuronal stathmins: a family of phosphoproteins cooperating for neuronal development, plasticity and regeneration. *Prog. Neurobiol.* **126**, 1–18 (2015).
54. Mason, M. R. J., Lieberman, A. R., Grenningloh, G. & Anderson, P. N. Transcriptional upregulation of SCG10 and CAP-23 is correlated with regeneration of the axons of peripheral and central neurons in vivo. *Mol. Cell. Neurosci.* **20**, 595–615 (2002).
55. Ozon, S., Byk, T. & Sobel, A. SCLIP: a novel SCG10-like protein of the stathmin family expressed in the nervous system. *J. Neurochem.* **70**, 2386–2396 (1998).

56. Wang, Q. *et al.* The landscape of multiscale transcriptomic networks and key regulators in Parkinson's disease. *Nature Communications* vol. 10 (2019).
57. Corti, S. *et al.* Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. *Sci. Transl. Med.* **4**, 165ra162 (2012).
58. Mori, N. & Morii, H. SCG10-related neuronal growth-associated proteins in neural development, plasticity, degeneration, and aging. *J. Neurosci. Res.* **70**, 264–273 (2002).
59. Grenningloh, G., Soehrman, S., Bondallaz, P., Ruchti, E. & Cadas, H. Role of the microtubule destabilizing proteins SCG10 and stathmin in neuronal growth. *J. Neurobiol.* **58**, 60–69 (2004).
60. Shin, J. E. *et al.* SCG10 is a JNK target in the axonal degeneration pathway. *Proc. Natl. Acad. Sci. U. S. A.* **109**, E3696–705 (2012).
61. Morii, H., Shiraishi-Yamaguchi, Y. & Mori, N. SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons. *J. Neurobiol.* **66**, 1101–1114 (2006).
62. Chou, C.-C. *et al.* PABPN1 suppresses TDP-43 toxicity in ALS disease models. *Hum. Mol. Genet.* **24**, 5154–5173 (2015).
63. Brais, B. *et al.* Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. *Nat. Genet.* **18**, 164–167 (1998).
64. Jenal, M. *et al.* The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. *Cell* **149**, 538–553 (2012).
65. Banerjee, A., Vest, K. E. & Pavlath, G. K. Nuclear poly (A) binding protein 1 (PABPN1) and Matrin3 interact in muscle cells and regulate RNA processing. *Nucleic acids* (2017).
66. Fan, X. *et al.* HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. *Can. J. Neurol. Sci.* **30**, 244–251 (2003).
67. Johnson, J. O. *et al.* Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. *Nat. Neurosci.* **17**, 664–666 (2014).
68. Senderek, J. *et al.* Autosomal-dominant distal myopathy associated with a recurrent missense mutation in the gene encoding the nuclear matrix protein, matrin 3. *Am. J. Hum. Genet.* **84**, 511–518 (2009).
69. Malik, A. M. *et al.* Matrin 3-dependent neurotoxicity is modified by nucleic acid binding and

- nucleocytoplasmic localization. *Elife* **7**, (2018).
70. Langfelder, P. *et al.* Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. *Nat. Neurosci.* **19**, 623–633 (2016).
71. Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. *BMC Bioinformatics* **9**, 559 (2008).
72. Zhang, B. & Horvath, S. A general framework for weighted gene co-expression network analysis. *Stat. Appl. Genet. Mol. Biol.* **4**, Article17 (2005).
73. Langfelder, P., Mischel, P. S. & Horvath, S. When is hub gene selection better than standard meta-analysis? *PLoS One* **8**, e61505 (2013).
74. Gregory, J. M., Fagegaltier, D. & Phatnani, H. Genetics of Amyotrophic Lateral Sclerosis. *Curr. Genet. Med. Rep.* (2020).
75. van Blitterswijk, M. *et al.* Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. *Mol. Neurodegener.* **9**, 38 (2014).
76. Greaves, C. V. & Rohrer, J. D. An update on genetic frontotemporal dementia. *J. Neurol.* **266**, 2075–2086 (2019).
77. Taylor, J. P., Brown, R. H., Jr. & Cleveland, D. W. Decoding ALS: from genes to mechanism. *Nature* **539**, 197–206 (2016).
78. Beckers, J., Tharkeshwar, A. K. & Van Damme, P. C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. *Autophagy* 1–17 (2021).
79. Gao, F.-B., Almeida, S. & Lopez-Gonzalez, R. Dysregulated molecular pathways in amyotrophic lateral sclerosis–frontotemporal dementia spectrum disorder. *EMBO J.* **36**, 2931–2950 (2017).
80. Zhang, K. *et al.* The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. *Nature* **525**, 56–61 (2015).
81. Freibaum, B. D. *et al.* GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. *Nature* **525**, 129–133 (2015).
82. Kim, H. J. & Taylor, J. P. Lost in Transportation: Nucleocytoplasmic Transport Defects in ALS and Other Neurodegenerative Diseases. *Neuron* **96**, 285–297 (2017).
83. Zhan, L., Hanson, K. A., Kim, S. H., Tare, A. & Tibbetts, R. S. Identification of Genetic Modifiers of TDP-43

- Neurotoxicity in *Drosophila*. *PLoS ONE* vol. 8 e57214 (2013).
84. Chou, C.-C. *et al.* TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. *Nat. Neurosci.* **21**, 228–239 (2018).
 85. Lui, K. & Huang, Y. RanGTPase: A Key Regulator of Nucleocytoplasmic Trafficking. *Mol. Cell. Pharmacol.* **1**, 148–156 (2009).
 86. Markmiller, S. *et al.* Context-Dependent and Disease-Specific Diversity in Protein Interactions within Stress Granules. *Cell* **172**, 590–604.e13 (2018).
 87. Cunningham, K. M. *et al.* TFEB/Mitf links impaired nuclear import to autophagolysosomal dysfunction in C9-ALS. *Elife* **9**, (2020).
 88. Culetto, E. & Legouis, R. *The ESCRT Complexes: Methods and Protocols*. (Humana, 2019).
 89. Jeong, S. SR proteins: Binders, regulators, and connectors of RNA. *Mol. Cells* **40**, 1–9 (2017).
 90. Cooper-Knock, J. *et al.* Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. *Brain* **137**, 2040–2051 (2014).
 91. Hautbergue, G. M., Hung, M.-L., Golovanov, A. P., Lian, L.-Y. & Wilson, S. A. Mutually exclusive interactions drive handover of mRNA from export adaptors to TAP. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 5154–5159 (2008).
 92. Walsh, M. J., Hautbergue, G. M. & Wilson, S. A. Structure and function of mRNA export adaptors. *Biochem. Soc. Trans.* **38**, 232–236 (2010).
 93. Snijders Blok, L. *et al.* Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling. *Am. J. Hum. Genet.* **97**, 343–352 (2015).
 94. Herdy, B. *et al.* Analysis of NRAS RNA G-quadruplex binding proteins reveals DDX3X as a novel interactor of cellular G-quadruplex containing transcripts. *Nucleic Acids Res.* **46**, 11592–11604 (2018).
 95. Conlon, E. G. *et al.* The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains. *Elife* **5**, (2016).
 96. Cheng, W. *et al.* CRISPR-Cas9 Screens Identify the RNA Helicase DDX3X as a Repressor of C9ORF72 (GGGGCC)_n Repeat-Associated Non-AUG Translation. *Neuron* vol. 104 885–898.e8 (2019).
 97. García, M. A., Meurs, E. F. & Esteban, M. The dsRNA protein kinase PKR: virus and cell control. *Biochimie* **89**, 799–811 (2007).

98. Taniuchi, S., Miyake, M., Tsugawa, K., Oyadomari, M. & Oyadomari, S. Integrated stress response of vertebrates is regulated by four eIF2 α kinases. *Sci. Rep.* **6**, 32886 (2016).
99. Mackenzie, I. R. *et al.* TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. *Neuron* **95**, 808–816 e9 (2017).
100. Liu-Yesucevitz, L. *et al.* Tar DNA binding protein-43 (TDP-43) associates with stress granules: analysis of cultured cells and pathological brain tissue. *PLoS One* **5**, e13250 (2010).
101. Meyer, C. *et al.* The TIA1 RNA-Binding Protein Family Regulates EIF2AK2-Mediated Stress Response and Cell Cycle Progression. *Mol. Cell* **69**, 622–635.e6 (2018).
102. Kim, H.-J. *et al.* Therapeutic modulation of eIF2 α phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. *Nature Genetics* vol. 46 152–160 (2014).
103. Lu, Y.-N. *et al.* MARK2 phosphorylates eIF2 α in response to proteotoxic stress. *PLoS Biol.* **19**, e3001096 (2021).
104. He, X. *et al.* Expression of a large family of POU-domain regulatory genes in mammalian brain development. *Nature* **340**, 35–41 (1989).
105. Ryu, E. J. *et al.* Misexpression of Pou3f1 results in peripheral nerve hypomyelination and axonal loss. *J. Neurosci.* **27**, 11552–11559 (2007).
106. Küsters, B. *et al.* TDP-43 accumulation is common in myopathies with rimmed vacuoles. *Acta Neuropathol.* **117**, 209–211 (2009).
107. Sasaki, S. & Maruyama, S. Immunocytochemical and ultrastructural studies of the motor cortex in amyotrophic lateral sclerosis. *Acta Neuropathol.* **87**, 578–585 (1994).
108. Zhu, Q. *et al.* The transcription factor Pou3f1 promotes neural fate commitment via activation of neural lineage genes and inhibition of external signaling pathways. *Elife* **3**, (2014).
109. Chen, X., Wang, J. W., Salin-Cantegrel, A., Dali, R. & Stifani, S. Transcriptional regulation of mouse hypoglossal motor neuron somatotopic map formation. *Brain Struct. Funct.* **221**, 4187–4202 (2016).
110. Collarini, E. J. *et al.* Down-regulation of the POU transcription factor SCIP is an early event in oligodendrocyte differentiation in vitro. *Development* **116**, 193–200 (1992).
111. Jaegle, M. *et al.* The POU factor Oct-6 and Schwann cell differentiation. *Science* **273**, 507–510 (1996).
112. Jensen, N. A., Pedersen, K. M., Celis, J. E. & West, M. J. Neurological disturbances, premature lethality,

- and central myelination deficiency in transgenic mice overexpressing the homeo domain transcription factor Oct-6. *J. Clin. Invest.* **101**, 1292–1299 (1998).
113. Bermingham, J. R., Jr *et al.* Tst-1/Oct-6/SCIP regulates a unique step in peripheral myelination and is required for normal respiration. *Genes Dev.* **10**, 1751–1762 (1996).
 114. Cairns, N. J. *et al.* Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. *Acta Neuropathologica* vol. 114 5–22 (2007).
 115. Mackenzie, I. R. A. *et al.* A harmonized classification system for FTLTDP pathology. *Acta neuropathologica* vol. 122 111–113 (2011).
 116. Mann, D. M. A. *et al.* Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. *Acta Neuropathol Commun* **1**, 68 (2013).
 117. Lee, H. *et al.* Cell Type-Specific Transcriptomics Reveals that Mutant Huntingtin Leads to Mitochondrial RNA Release and Neuronal Innate Immune Activation. *Neuron* **107**, 891–908.e8 (2020).
 118. Mohammadi, S., Ravindra, V., Gleich, D. F. & Grama, A. A geometric approach to characterize the functional identity of single cells. *Nat. Commun.* **9**, 1516 (2018).
 119. Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. *F1000Res.* **5**, 2122 (2016).
 120. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
 121. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
 122. Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). *Nucleic Acids Res.* **47**, W191–W198 (2019).
 123. Schindelin, J. *et al.* Fiji: an open-source platform for biological-image analysis. *Nat. Methods* **9**, 676–682 (2012).